<?xml version="1.0" encoding="UTF-8"?>
<p>While a robust assessment of the safety of the NBM-based medical applications for the patients is a prerequisite for regulatory approval [
 <xref rid="B10-materials-13-04532" ref-type="bibr">10</xref>], the assessment and management of the possible occupational and/or environmental risks resulting from unintentional exposure to these materials are not strictly required by the European Medicines Agency (EMA) and the national medicinal regulations, and are therefore often overlooked. 
</p>
